A turn for the worse: Aβ β-hairpins in Alzheimer's disease

Sarah M Ruttenberg1, James S Nowick1

  • 1Department of Chemistry, University of California, Irvine, Irvine, CA 92697-2025, United States.

PubMed

Insights

Amyloid-β (Aβ) oligomers drive Alzheimer's disease (AD) neurodegeneration. Targeting Aβ β-hairpins offers a promising strategy for developing selective antibody therapies against toxic oligomers in AD.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Immunology

Background:

  • Amyloid-β (Aβ) oligomers are implicated in Alzheimer's disease (AD) neurodegeneration.
  • Studying these soluble Aβ aggregates is challenging due to their instability and heterogeneity.
  • Various methods, including mutations and cross-linking, are used to stabilize Aβ oligomers for research.

Purpose of the Study:

  • To review research on Aβ peptides in β-hairpin conformations.
  • To discuss the role of Aβ β-hairpins in AD pathogenesis.
  • To explore the relevance of Aβ β-hairpins in therapeutic drug development.

Main Methods:

  • Literature review of studies on Aβ β-hairpins.
  • Analysis of proposed Aβ oligomer structures, including those with β-hairpin conformations.
  • Examination of strategies for isolating and stabilizing Aβ oligomers.

Main Results:

  • Aβ peptides can adopt multiple β-hairpin conformations.
  • These β-hairpin structures are considered building blocks of toxic Aβ oligomers.
  • Aβ β-hairpins show potential as epitopes for targeted antibody therapies.

Conclusions:

  • Aβ β-hairpin conformations are crucial in AD pathogenesis.
  • Targeting Aβ β-hairpins with antibodies may be more effective than targeting linear or fibrillar Aβ.
  • Aβ β-hairpins represent a viable target for developing novel AD therapeutics.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183